Protherics PLC
Notification of Major Interests in Shares
London, UK; Brentwood, TN, US: 29 August 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that today, in
accordance with the Transparency Obligations
Directive, a notification of interest in the ordinary share capital of
the Company was received from Invesco Perpetual on behalf of Invesco
Limited. Details of the interest notified are as follows:
1. Reason for the notification (please tick the appropriate box
or boxes)
An disposal of voting rights Yes
An acquisition or disposal of financial instruments which may
result in the acquisition of shares already issued to which voting
rights are attached
An event changing the breakdown of voting rightsOther (please specify):
2. Full name of person(s) subject to the Invesco Limited
notification obligation:
3. Full name of shareholder(s) (if different
from 2.):
4. Date of the transaction (and date on which 28 August 2008
the threshold is crossed or reached if
different):
5. Date on which issuer notified: 29 August 2008
6. Threshold(s) that is/are crossed or crossed 11% threshold to
reached: 10%
7. Notified details:
A: Voting rights attached to shares
Class/type of Situation previous to Resulting situation after the trigg
ering
shares the Triggering transaction
transaction
if possible
using the ISIN Number of Number of Number of Number of voting % of v
oting
CODE Shares Voting shares rights rights
Rights
Direct Indirect Direct
Indirect
37,361,912 37,361,912 36,519,411 36,519,411
10.67%
Ordinary 2P
Shares
(GB0007029209)
B: Financial Instruments
Resulting situation after the triggering transaction
Type of Expiration Exercise/ Number of voting rights that % of
financial date Conversion may be acquired if the voting
instrument Period/ instrument is exercised/ rights
Date converted.
Total (A+B)
Number of voting rights % of voting rights
36,519,411 10.67%
8. Chain of controlled undertakings through which the voting rights and
/or the financial instruments are effectively held, if applicable :
JP Morgan Chase - 6,604,464
Citibank - 29,918,947
Proxy Voting:
9. Name of the proxy holder:
10. Number of voting rights proxy holder will cease to hold:
11. Date on which proxy holder will cease to hold voting rights:
12. Additional information:
/ Ends /
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
Contact Information: Contacts: RNS Customer Services 0044-207797-4400 http://www.rns.com